POINT Biopharma Publishes Preclinical Data for Actinium-Labelled PNT2001, a Next-Generation PSMA Ligand, at EANM's Annual Congress
globenewswire.com
news
2022-10-17 00:00:00

PNT2001 displays enhanced internalization, biodistribution, and pre-clinical efficacy in multiple tumor models, making it a prime candidate for the delivery of actinium-225 Targeting IND/CTA submission for PNT2001 program in H1 2023 INDIANAPOLIS, Oct. 17, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the 'Company' or 'POINT'), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced the publication of promising new pre-clinical data from the Company's next-generation radioligand therapy (RLT) program for prostate cancer, PNT2001.
